Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China

Nature·Apr 14

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research is being conducted on the use of CDK4/6 inhibitors for advanced or metastatic breast cancer, specifically in the context of second-line treatment for HR+/HER2− cases. The cost-effectiveness of these inhibitors is being examined, with studies such as the SONIA trial providing insights into their potential benefits. The effectiveness and optimal sequencing of CDK4/6 inhibitors in treating this type of breast cancer are being explored in various studies and reviews.

Full coverage

The SONIA trial: redefining “better” in the sequencing of CDK4/6 inhibitors for advanced breast cancer

Frontiers·Apr 24

Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial

Nature·Mar 30

Pharmacologic management of HR+/HER2− mBC: a clinically oriented review

Frontiers·Aug 8

Maximizing the Potential of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

Cancer Therapy Advisor·Jun 8

CDK4/6 Inhibitors May Be Better Suited in the Second-Line for Patients With ER+, HER2– Breast Cancer

Oncology Nursing News·Jun 21

Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER-Medicare population-based study

Wiley & Sons·Feb 9

SONIA: Integrating Cost and Toxicity in Metastatic Breast Cancer Care

Oncology News Central·Aug 24

First Results of the Dutch SONIA Trial on CDK4/6 Inhibitors

Oncodaily·Nov 30

View original report at Nature ↗

Fetching the latest headlines…